Publications:

Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib.

American Journal Of Hematology

Cortes, Jorge E JE; Khoury, Hanna J HJ; Kantarjian, Hagop M HM; Lipton, Jeff H JH; Kim, Dong-Wook DW; Schafhausen, Philippe P; Matczak, Ewa E; Leip, Eric E; Noonan, Kay K; Brümmendorf, Tim H TH; Gambacorti-Passerini, Carlo C

Publication Date: 2016-12

Variant appearance in text: HR: L248R

PubMed Link: 27531525

Variant Present in the following documents:

• Main text
• AJH-91-1206.pdf

View BVdb publication page

Refining targeted therapies in chronic myeloid leukemia: development and application of nilotinib, a step beyond imatinib.

Oncotargets And Therapy

Breccia, Massimo M; Alimena, Giuliana G

Publication Date: 2008-10-01

Variant appearance in text: HR: L248R

PubMed Link: 21127752

Variant Present in the following documents:

• Main text

View BVdb publication page

Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review.

Core Evidence

Jabbour, Elias E; Cortes, Jorge J; Kantarjian, Hagop H

Publication Date: 2010-06-15

Variant appearance in text: HR: L248R

PubMed Link: 20694077

Variant Present in the following documents:

• Main text
• ce-4-207.pdf

View BVdb publication page